Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
October 17, 2021 4:20 PM EDTIn the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observedThe totality of evidence from VALOR and its ongoing open-label extension showed that participants who started tofersen earlier experienced better outcomes, further suggesting a positive clinical effectTopline data being presented today at the American Neurological Association 2021 Annual MeetingGiven the high unmet medical need, Biogen will expand its ongoing early access program (EAP) to the broader... More
